Argenx (ARGX) announced its plan to advance the clinical development of ARGX-119, an agonist antibody to muscle-specific kinase, to a registrational study in patients with congenital myasthenic syndromes following the analysis of topline data from the Phase 1b study. Detailed results will be presented at a future medical meeting.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Efgartigimod Study: A Promising Step for ITP Treatment
- Promising Growth Prospects for Argenx Se’s Vyvgart in CIDP and gMG Treatment Drive Buy Rating
- Argenx Gains European Approval for Novel CIDP Treatment
- Argenx price target lowered to EUR 650 from EUR 715 at Morgan Stanley
- Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP